Omnicef 125Mg/5ml (80ml) Suspension

Active Ingredient: Cefdinir Acute bacterial otitis media: Treatment of acute bacterial otitis media in pediatric patients caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only) and Moraxella catarrhalis (including beta-lactamase-producing strains). Acute exacerbations of chronic bronchitis: Treatment of acute exacerbations of chronic bronchitis in adults and adolescents caused by H. influenzae (including beta-lactamase producing strains), H. parainfluenzae (including beta-lactamase-producing strains), S. pneumoniae (penicillin-susceptible strains only) and M. catarrhalis (including beta-lactamase-producing strains). Acute maxillary sinusitis: Treatment of acute maxillary sinusitis in adults and adolescents caused by H. influenzae (including beta-lactamase-producing strains), S. pneumoniae(penicillin-susceptible strains only) and M. catarrhalis (including beta-lactamase-producing strains). Note: Limitations of use: According to the IDSA guidelines for acute bacterial rhinosinusitis, cefdinir is no longer recommended as monotherapy for initial empiric treatment (Chow 2012). Community-acquired pneumonia: Treatment of community-acquired pneumonia in adults and adolescents caused by H. influenzae (including beta-lactamase-producing strains), H. parainfluenzae (including beta-lactamase-producing strains), S. pneumoniae (penicillin-susceptible strains only) and M. catarrhalis (including beta-lactamase-producing strains). Pharyngitis/Tonsillitis: Treatment of pharyngitis/tonsillitis in adults, adolescents, and pediatric patients caused by S. pyogenes. Skin and skin structure infections, uncomplicated: Treatment of uncomplicated skin and skin structure infections in adults, adolescents, and pediatric patients caused by Staphylococcus aureus (including beta-lactamase-producing strains) and S. pyogenes